CD1D and neoplasm: In conclusion, the similar percentages of activated iNKT cells stimulated by αGC-pulsed APCs or by tumor-targeted αGC/sCD1d-anti-HER2 protein did not correlate with a similar killing of SKBR3 tumor cells, but rather with the concomitant elimination of the αGC/APCs, as shown by, respectively, 26 and 36 % of Annexin V+ αGC/C1R-CD1d and αGC/moDCs (Fig. 4a).